Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase NA 1

Status

Completed 4Recruiting 3Not yet recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 152Breast Neoplasms 146Neoplasms 143Neoplasm Metastasis 142Colorectal Neoplasms 137Recurrence 105Ovarian Neoplasms 101Pancreatic Neoplasms 83Advanced Solid Tumor 82Lung Neoplasms 81Multiple Myeloma 77Prostatic Neoplasms 75Advanced Solid Tumors 74Stomach Neoplasms 73Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 68Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 64Triple Negative Breast Neoplasms 59Lymphoma, B-Cell 55Endometrial Neoplasms 54Myelodysplastic Syndromes 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma 52Glioma 51Brain Neoplasms 46Carcinoma, Renal Cell 44Hematologic Neoplasms 43

Interventions

trametinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Solid Tumor Cancer × Clear all
NCT07467629 2026-05-19

QLS5212 for Participants With Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1 Recruiting
100 enrolled
Other solid neoplasm

Solid Tumor Cancer

NCT07584954 2026-05-13

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

ImmunoUrchin

Phase 1 Recruiting
90 enrolled
Other solid neoplasm

Solid Tumor Cancer

NCT06962254 2025-05-08

Imatinib and Trametinib for KRAS-mutated Solid Tumor

China Medical University Hospital

Phase 1 Recruiting
10 enrolled
Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡